Cite this page: Parsons J. Danaparoid (Orgaran). PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/coagulationdanaparoid.html. Accessed May 29th, 2020.
Definition / general
- Approved to prevent deep venous thromboses
- Also an alternative to heparin for patients with heparin induced thrombocytopenia (Crit Care 2007;11:R102)
- Use is decreasing due to newer anticoagulants
- Composed of low molecular weight glycosaminoglycans (mixture of heparan sulfate, dermatan sulfate and chondroitin sulfate) that primarily inhibit factor Xa, factor IIa to a much lesser extent
- Similar to low molecular weight heparin in having a more predictable anticoagulant effect, with less need for laboratory monitoring
- Monitor, if desired, by measuring inhibitor of factor Xa using standard curve; draw 6 hours after subcutaneous injection; PT and PTT are unaffected
- Therapeutic levels to treat DVT are 0.5 - 0.8 anti-factor Xa units/ml, lower for DVT prophylaxis
- Long half-life, is prolonged with renal failure
- No reversal agent is known, but incomplete reversal is shown with protamine sulfate
- Not marketed in the US since 2004, still available in some countries.